{"id":"W4413801718","doi":"10.1016/j.annonc.2025.08.008","title":"Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Eisai Canada","keywords":"Pembrolizumab; Medicine; Lenvatinib; Placebo; Oncology; Internal medicine; Double blind; Phases of clinical research; Metastatic melanoma; Immunotherapy; Clinical trial; Cancer; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001933358,0.00227837,0.00415727,0.0005514385,0.0006105903,0.001641898,0.001794643,0.002017764,0.01165676],"category_scores_gemma":[0.001582612,0.001159996,0.00192152,0.0004935768,0.001794187,0.001482108,0.0005466403,0.005325874,0.002427482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001281002,"about_ca_system_score_gemma":0.001873159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002077214,"about_ca_topic_score_gemma":0.004091309,"domain_scores_codex":[0.9993628,0.0003113975,0.00002867709,0.0001299875,0.00004886891,0.0001182643],"domain_scores_gemma":[0.9990682,0.0002579606,0.0001658325,0.00009159582,0.00005557925,0.000360845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9826891,0.006055193,0.000148428,0.0002729486,0.0005328943,0.00001794501,0.00002566569,0.0002699596,0.001633597,0.00009800273,0.0007099721,0.007546202],"study_design_scores_gemma":[0.9757092,0.02290985,0.0004111618,0.000008902959,0.0001492272,0.00001052729,0.00000863176,0.0002689544,0.0001740906,0.00008173341,0.0002599607,0.000007745344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748635,0.004132885,0.001765274,0.001248614,0.00155232,0.007143873,0.003014299,0.0005401722,0.005738887],"genre_scores_gemma":[0.9730244,0.002438674,0.002704368,0.002261885,0.0006813953,0.007618194,0.001934454,0.00009071616,0.009245935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01165676,"threshold_uncertainty_score":0.03899574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1955929596440084,"score_gpt":0.4627367715875191,"score_spread":0.2671438119435107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}